SLS stock is trending due to SELLAS Life Sciences reporting its first-quarter financial results. The company announced a Q1 loss of $0.05 per share, which was better than the estimated $0.06 loss. The company also provided a trial update, contributing to the stock's movement.
Get the full breakdown — why it matters, background context, and what comes next.
Read Full Analysis